Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke

NCT00141011 is registered in ClinicalTrials.gov with Neurobiological Technologies as lead sponsor.

NCT NCT00141011
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00141011 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke
Lead sponsor
Neurobiological Technologies
Phase
Phase 3
Overall status
Terminated
Start date
September 30, 2005
Completion date
December 31, 2008
Enrollment
277 (actual)
Sites
100

Conditions

As the registry lists them; a condition with its own page is linked.

brain infarction, cerebral ischemia, stroke